INCIT 2022 congress – Nantes, FR
September 22, 2022

Stéphane Depil, founder and CEO of ErVaccine Technologies,  will give a talk  entitled “Human Endogenous Retrovirus  Represent a Source of Shared Tumor Epitopes Inducing High-Avidity Cytotoxic T cells for Cancer Immunotherapy” at INCIT 2022 congress (Session #1 “New concepts & new targets in Immunotherapy” planned on Monday 26 September at 4:30 pm)

For more information visit: INCIT 2022 congress

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice

Navigation

> Home

> About us

> Sciences

> Investors

> Join us

> Contact

Contact

28 RUE LAENNEC
69008 
LYON FRANCE

contact@ervimmune.com

+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go